时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
However, since patients with AMD are typically older, they are more likely to have multiple comorbidities, often resulting in polypharmacy.；Despite several studies addressing this issue, evidence remains limited, and the association between specific medications and AMD development is not fully established.；However, the potential role of cumulative anticholinergic exposure in retinal neurodegeneration and AMD development remains insufficiently explored.
方法
Ethical approval was obtained from the Institutional Ethics Committee (No: 2023/2/16), and the study was conducted in accordance with the Declaration of Helsinki.；Written informed consent was obtained from all participants prior to enrollment.；Accordingly, participants were classified into two groups: Fifty-five participants aged 55–90 years diagnosed with geographic atrophy.；Forty-seven age-matched participants who presented to the same ophthalmology outpatient clinic for routine ophthalmic examination or refractive complaints and had no evidence of chronic ocular disease.
核心结论
There were no significant differences between the GA secondary to AMD and control groups in terms of age (72.9 ± 13.1 vs. 74.2 ± 9.1 years, p = 0.539), gender distribution (58.2% vs. 48.9% female, p = 0.426), Charlson Comorbidity Index scores (median: 1 [0–4] in both groups, p = 0.777), or multimorbidity prevalence (43.6% vs. 51.1%, p = 0.551).；Medication-related variables differed significantly between the groups.；The median number of medications was higher in the GA secondary to AMD group compared to controls (3 [0–8] vs. 1 [0–6], p = 0.010). ‖ 结论：These findings suggest an association between cumulative medication exposure and GA; however, causality cannot be inferred due to the observational design of the study.
局限
Due to the observational design, these findings should be interpreted as an association rather than evidence of causality.；First, its observational case-control design precludes causal inference and may be associated with potential selection bias due to recruitment from a single tertiary ophthalmology clinic.；The possibility that some medications were not included due to incomplete medical records or patients’ inability to recall previous medication use should be considered as a limitation of the study.
对本项目的价值
★☆☆☆☆ 皮肤是唯一可直接局部给药、可活检、可影像量化的器官，最快可验证 senotherapeutic 概念。
全文来源
PMC JATS 全文（正文 15,984 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Association between anticholinergic burden and geographic atrophy secondary to age-related macular degeneration: a case-control study.
- 期刊与标识：BMC Ophthalmol · PMID 42958104 · DOI 10.1186/s12886-026-05184-y
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。